Reporting Suspected or Actual Violations Sample Clauses

Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000.
Sample 1Sample 2Sample 3See All (12)
AutoNDA by SimpleDocs
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e- mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at +0-000-000-0000. Individuals employed from the following Government Bodies with which Pfizer commonly interacts are automatically considered GOs in Canada:
Sample 1Sample 2Sample 3See All (4)
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at +1-212-733- 3026. Schedule FCPA1 - Government Bodies with which Pfizer Commonly Interacts: • Health Canada • Industry Canada • Privy Council Office • Prime Minister's Office • Foreign Affairs and International Trade • Patented Medicine Prices Review Board • Veterans Affairs Canada • National Defence • Finance Canada • Royal Canadian Mounted Police • Common Drug Review (CDR) • Canadian Agency for Drugs and Technologies in Health (CADTH) • Réseaux locaux de services de santé et de services sociaux (CISSS, CIUSSS) (Québec) • Groupes de médecine familiale (Québec) • Cliniques réseau (CR or CMA) (Québec) • Local Health Integration Network (Ontario) • Family Health Teams (Ontario) • Regional Health Authorities (Western Canada) • Canadian Food Inspection Agency • Veterinary Drugs Directorate • Aquaculture Canada • Integrated Health Agencies (Atlantic Canada) Examples of Government Officials Include: • Elected or appointed Government Officials; • Public servants; • Declared political candidates (whether for party nomination or election); • HCPs who meet the criteria set forth in the definition of Government Official, e.g., HCPs employed by (a) the military, (b) the Correctional Service of Canada (prisons and penitentiaries), or (c) government operated or controlled hospitals or institutions (e.g., mental institutions, veterans affairs hospitals) and HCPs serving on government task forces or committees (e.g., Management of Severe Pain Advisory Committee of Experts, AIDS Advisory Committee, National Advisory Council on Aging, Medical Advisors Group); • HCPs that are officers / directors of, employed by or affiliated with, any publicly funded health care institution (e.g. hospital, clinic etc.) or institute of higher learning (e.g. college, CEGEP, university etc.); • Officers, employees or individuals who act in an official capacity on behalf of the United Nations, World Health Organization, World Trade Organization, International Joint Commission – United States and Canada, International Committee of the Red Cross, North American ...
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Xxxxxx, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Upjohn, or if a Business Associate prefers, to Xxxxxx’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at +0-000-000-0000. Individuals employed from the following Government Bodies with which Upjohn commonly interacts are automatically considered GOs in Canada:
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and AntiCorruption Principles or the law. Such reports can be made to a Business Associate's primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer's Compliance Group by email at corporate. xxxxxxxxxx@xxxxxx.xxx or by phone at 1-212- 000-0000. Za Obdarovaneho / For the Beneficiary: Ona/ Date: Name/ Meno a priezvisko: prof. MUDr. Juraj Šteňo, DrSc. Podpis / Signature: ani nepriamo vykonávať, sľubovať alebo schvaľovať' vykonanie korupčnej platby, ani poskytnúť čokoľvek cenne akejkoľvek osobe s cieľom primäť poskytnúť' nezákonnú obchodnú výhodu spoločnosti Pfizer.  Obchodní partneri a osoby jednajúce v ich mene v spojení s pracou pre spoločnosť Pfizer nesmú priamo ani nepriamo vyžadovať', súhlasiť' s prijatím alebo prijať platbu alebo čokoľvek hodnotne ako nepatričnú ponuku v spojení s obchodnou činnostnou pre spoločnosť' Pfizer.  Zamestnanci spoločnosti Pfizer majú zakázané od obchodných partnerov a osôb jednajúcich v ich mene v spojení s pracou pre spoločnosť' Pfizer prijímať' dary, služby, výhody, zábavu alebo iné položky väčšie ako symbolické alebo zanedbateľné peňažné hodnoty. Okrem toho sú dary zanedbateľnej hodnoty povolene iba pokiaľ sú prijímane len občas a pri vhodných príležitostiach. Ohlasovanie porušenia alebo podozrenia na porušenie obchodní partneri a osoby jednajúce v ich mene v spojení s pracou pre spoločnosť' Pfizer majú povinnosť' ohlásiť' podozrenie na potenciálne porušenie týchto medzinárodných zásad proti úplatkárstvu a korupcii alebo zákona. Hlásenie je možné poslať' primárnej kontaktnej osobe obchodného partnera v spoločnosti Pfizer alebo e-mailom na adresu: corporate. compliance@pfizer. com, pripadne telefonicky na čísle 1-212- 733-3026. Za Obdarovaného / For the Beneficiary: Ona/ Date: Name/ Meno a priezvisko: prof. MUDr. Juraj Šteno, DrSc.
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000. Provision of Services (the “Terms and Conditions”) Page: 8 of 8 SCHEDULE B ANNUAL COMPLIANCE CERTIFICATE We, the Supplier hereby certify:
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for XXX, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at XXX, or if a Business Associate prefers, to XXX’s Compliance Group by e-mail at XXXX or by phone at XXXX. Attachment C EQUIPMENT AND MATERIALS NOT APPLICABLE Attachment D PROTECTION OF PERSONAL DATA
Sample 1
AutoNDA by SimpleDocs
Reporting Suspected or Actual Violations. In conducting Pfizer-related activities, Business Associates, and those acting on behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if an Associate prefers, to Pfizer’s Compliance Group, by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000. Schedule 1.14 Compounds [*****] [End of Schedule 1.14] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not materia l and would likely cause competitive harm to the Registrant if publicly disclosed. Schedule 3.4.1 Marginal Royalty Rate Calculation Example By way of example only, if Net Sales by Pfizer, its Affiliates or its Sublicensees in the Territory during a Pfizer Year are $3.2 billion, then the royalties payable by Pfizer under Section 3.4.1 during such Pfizer Year would be calculated as follows: Royalty payable for applicable Pfizer Year [*****] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not material and would likely cause competitive harm to the Registrant if publicly disclosed. Schedule 2.6 Technology Transfer [*****] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not material and would likely cause competitive harm to the Registrant if publicly disclosed. Schedule 6.4.1 Theravance Press Release [attached] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not material and would likely cause competitive harm to the Registrant if publicly disclosed. Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program Topically-Applied, Skin-Selective Pan-JAK Inhibitors Specifically Designed to Target Pro-Inflammatory Pathways with Minimal Systemic Exposure DUBLIN, IRELAND AND NEW YORK – December 23, 2019 – Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that the companies have entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinas...
Sample 1

Related to Reporting Suspected or Actual Violations

  • No Undisclosed Events, Liabilities, Developments or Circumstances No event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced, (ii) could have a material adverse effect on any Buyer’s investment hereunder or (iii) could have a Material Adverse Effect.

  • No Violation of Environmental Laws There is no pending action or proceeding directly involving the Mortgaged Property in which compliance with any environmental law, rule or regulation is an issue; there is no violation of any environmental law, rule or regulation with respect to the Mortgaged Property; and nothing further remains to be done to satisfy in full all requirements of each such law, rule or regulation constituting a prerequisite to use and enjoyment of said property;

  • Material Changes; Undisclosed Events, Liabilities or Developments Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on Schedule 3.1(i), (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.

  • Disclosure Updates Promptly and in no event later than 5 Business Days after obtaining knowledge thereof, notify Agent if any written information, exhibit, or report furnished to the Lender Group contained, at the time it was furnished, any untrue statement of a material fact or omitted to state any material fact necessary to make the statements contained therein not misleading in light of the circumstances in which made. The foregoing to the contrary notwithstanding, any notification pursuant to the foregoing provision will not cure or remedy the effect of the prior untrue statement of a material fact or omission of any material fact nor shall any such notification have the effect of amending or modifying this Agreement or any of the Schedules hereto.

  • Business Activities; Change of Legal Status and Organizational Documents The Credit Parties shall not: (i) engage in any line of business other than the businesses engaged in on the date hereof and business reasonably related thereto; (ii) change its name, its type of organization, its jurisdictions of organization or other legal structure; or (iii) permit its articles of incorporation (including any certificates of designation, is applicable), bylaws, operating agreement, partnership agreement, certificate of organization or similar governing or organizational documents to be amended or modified in any way which could reasonably be expected to have a Material Adverse Effect.

  • Non-Violation Section 1. It shall not be a violation of this Agreement, if an Employee or Employees cease work because of:

  • Governmental Filings; No Violations (i) Other than the necessary filings, notices, reports, consents, registrations, approvals, permits, expirations of waiting periods or authorizations (A) pursuant to Section 1.3, (B) required under the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act of 1976, as amended (the “HSR Act”) or any applicable foreign competition Laws (the “Foreign Competition Laws”) in connection with the Merger, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Securities Act of 1933, as amended (the “Securities Act”), (C) to comply with state securities or “blue-sky” Laws and (D) as may be required with or to foreign and transnational Governmental Entities pursuant to applicable foreign and transnational Laws regarding the provision of broadcasting or audio-visual media services (such Governmental Entities, “Foreign Regulators”, and such Laws, “Foreign Regulatory Laws”), no filings, notices and/or reports are required to be made by the Company or its Subsidiaries with, nor are any consents, registrations, approvals, permits, expirations of waiting periods or authorizations required to be obtained by the Company or its Subsidiaries from, any domestic, foreign, multinational or transnational governmental, competition or regulatory authority, court, arbitral tribunal, commission, body or other legislative, executive or judicial governmental entity or self-regulatory agency (including any political subdivision thereof or any state-owned or state-controlled enterprise) (each, a “Governmental Entity”) in connection with the execution, delivery and performance of this Agreement by the Company and/or the consummation by the Company of the Merger and the other transactions contemplated hereby, except, in each case, those that the failure to make or obtain would not, individually or in the aggregate, reasonably be likely to have a Company Material Adverse Effect or prevent, materially delay or materially impair the ability of the Company to consummate the Merger.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!